Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500114651) titled 'Exploratory Clinical Study of Fruquintinib Combined with Sintilimab and Chemotherapy as Adjuvant Treatment for Stage III Gastric Cancer after Surgery' on Dec. 16, 2025.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: The First Affiliated Hospital of Anhui Medical University
Condition:
pathological stage III (pIII) gastric adenocarcinoma and gastroesophageal junction adenocarcinoma after surgery.
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2025-12-22
Target Sample Size: experimental group:32;
Countries of Recruitment:
China
To know more, visit htt...